Abstract:Mutation of isocitrate dehydrogenase 2 (IDH2) is a key factor in promoting cytarabine (Ara‐C) resistance in acute myeloid leukemia (AML), however the underly mechanism remains unclear. Acute myeloid leukemia cells, were cultured with either IDH2 knockdown (KD‐IDH2) or overexpression (OE‐IDH2) to elucidate the role of IDH2 in these leukemic cell lines. Additionally, mutant cell lines were engineered to replicate clinically relevant IDH2 mutations. To investigate cellular responses, the glycolytic inhibitor 2‐deoxy‐D‐glucose (2‐DG) was administered to the cells. Cell proliferation was quantified using a Cell Counting Kit‐8 (CCK‐8), while apoptosis was evaluated through propidium iodide staining followed by flow cytometry. Glycolytic metabolism levels were measured using a specific reagent kit, and Western blotting was employed to determine the expression levels of glycolysis‐related proteins. Transcriptome sequencing was conducted to elucidate the mechanisms by which IDH2 mutations influence glycolysis. Furthermore, both in vitro cell experiments and in vivo subcutaneous transplantation tumor models in nude mice were utilized to validate these mechanisms. OE‐IDH2 in AML cells, enhances resistance to the Ara‐C, promotes cell proliferation and glycolysis, and inhibits apoptosis. KD‐IDH2 exhibits opposite effects. Both IDH2 mutations and OE‐IDH2 produce similar effects on these cellular processes. The increase in glycolysis levels following IDH2 mutation may contribute to the reduced efficacy of Enasidenib in inhibiting the proliferation of IDH‐mutant AML cells. Transcriptome sequencing results indicate an enrichment of the PI3K/Akt signaling pathway in IDH2‐mutant AML cells. BEZ235 significantly inhibits the expression of phosphorylated PI3K (p‐PI3K), phosphorylated Akt (p‐Akt), mTOR, glycolytic metabolism, and Ara‐C resistance both in vitro and in vivo. Overexpression and mutation of IDH2 coordinate with the Warburg effect through the PI3K/Akt/mTOR pathway to promote Ara‐C resistance in AML.

Data from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Supplementary Figures and Figure Legends from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Table S3 from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Table S1 from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Table S2 from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors

Isocitrate dehydrogenases 2-mediated dysfunctional metabolic reprogramming promotes intestinal cancer progression via regulating HIF-1A signaling pathway

E2F1 Transactivates IQGAP3 and Promotes Proliferation of Hepatocellular Carcinoma Cells Through IQGAP3-mediated PKC-alpha Activation.

P89.07 A Large-Scale Survey of IDH1/2 Mutation in Chinese Patients with NSCLC

APC/C-regulated CPT1C promotes tumor progression by upregulating the energy supply and accelerating the G1/S transition

Metabolic Reprogramming of Cancer-Associated Fibroblasts by IDH3α Downregulation.

Metabolic Reprogramming of Cancer-Associated Fibroblasts by Idh3 Alpha Downregulation

Down-Regulation of CIDEA Promoted Tumor Growth and Contributed to Cisplatin Resistance by Regulating the JNK-p21/Bad Signaling Pathways in Esophageal Squamous Cell Carcinoma

Ten‐Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wild‐Type Isocitrate Dehydrogenase 1

CDK7-YAP-LDHD axis promotes D-lactate elimination and ferroptosis defense to support cancer stem cell-like properties

Cyclin D1 extensively reprograms metabolism to support biosynthetic pathways in hepatocytes

HDAC2 Regulates Cell Proliferation, Cell Cycle Progression and Cell Apoptosis in Esophageal Squamous Cell Carcinoma EC9706 Cells

The Regulatory Mechanisms and Inhibitors of Isocitrate Dehydrogenase 1 in Cancer

Characteristic ASS1 and PYCR1 Maintain Esophageal Squamous Cell Carcinoma Development under Limited Nutrient Conditions

O-GlcNAcylation of Keratin 18 Coordinates TCA Cycle to Promote Cholangiocarcinoma Progression

Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect